Prevalence and incidence of hypoglycaemia in 532,542 people with type 2 diabetes on oral therapies and insulin: A systematic review and meta-analysis of population based studies

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Edridge, Chloe L ^a   Dunkley, Alison J ^b   Bodicoat, Danielle H ^b   Rose, Tanith C ^b   Gray, Laura J ^a   Davies, Melanie J ^b   Khunti, Kamlesh ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; SULFONYLUREA; ANTIDIABETIC AGENT;

ANGINA PECTORIS; ARTICLE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CONGESTIVE HEART FAILURE; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; EMERGENCY WARD; ETHNICITY; HEART DISEASE; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INCIDENCE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREVALENCE; PROSPECTIVE STUDY; QUALITY CONTROL; QUESTIONNAIRE; RETROSPECTIVE STUDY; RISK REDUCTION; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; COMPLICATION; DIABETES MELLITUS, TYPE 2; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; PREVALENCE;

EID: 84935511058     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126427     Document Type: Article

References (47)

1. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabetic medicine: a journal of the British Diabetic Association. 2012; 29(7):855-62.
2. Feinkohl I, Aung PP, Keller M, Robertson CM, Morling JR, McLachlan S, et al. Severe Hypoglycemia and Cognitive Decline in Older People With Type 2 Diabetes: The Edinburgh Type 2 Diabetes Study. Diabetes care. 2014; 37(2):507-15. doi: 10.2337/dc13-1384 PMID: 24103900
3. Bloomfield HE, Greer N, Newman D, MacDonald R, Carlyle M, Fitzgerald P, et al. Predictors and Consequences of Severe Hypoglycemia in Adults with Diabetes - A Systematic Review of the Evidence. VA Evidence-based Synthesis Program Reports. Washington (DC)2012.
4. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, et al. Severe Hypoglycemia and Risks of Vascular Events and Death. New England Journal of Medicine. 2010; 363(15):1410-8. doi: 10.1056/NEJMoa1003795 PMID: 20925543
5. Stargardt T, Gonder-Frederick L, Krobot KJ, Alexander CM. Fear of hypoglycaemia: defining a minimum clinically important difference in patients with type 2 diabetes. Health and quality of life outcomes. 2009; 7:91. doi: 10.1186/1477-7525-7-91 PMID: 19849828
6. Vexiau P, Mavros P, Krishnarajah G, Lyu R, Yin D. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. Diabetes, obesity & metabolism. 2008; 10 Suppl 1:16-24.
7. Williams SA, Pollack MF, Dibonaventura M. Effects of hypoglycemia on health-related quality of life, treatment satisfaction and healthcare resource utilization in patients with type 2 diabetes mellitus. Diabetes research and clinical practice. 2011; 91(3):363-70. doi: 10.1016/j.diabres.2010.12.027 PMID: 21251725
8. Wild D, von Maltzahn R, Brohan E, Christensen T, Clauson P, Gonder-Frederick L. A critical review of the literature on fear of hypoglycemia in diabetes: Implications for diabetes management and patient education. Patient Education and Counseling. 2007; 68(1):10-5. PMID: 17582726
9. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012; 55(6):1577-96. doi: 10.1007/s00125-012-2534-0 PMID: 22526604
10. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. The New England journal of medicine. 1993; 329(14):977-86. PMID: 8366922
11. Excellence NIfHaC. Type 2 diabetes: The management of type 2 diabetes. London: National Institute for Health and Care Excellence: 2009.
12. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a metaanalysis of randomised controlled trials. Lancet. 2009; 373(9677):1765-72. doi: 10.1016/S0140-6736(09)60697-8 PMID: 19465231
13. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352 (9131):854-65. PMID: 9742977
14. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. PMID: 9742976
15. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA: the journal of the American Medical Association. 2010; 303(14):1410-8. doi: 10.1001/jama.2010.405 PMID: 20388897
16. Schwarz PE. Report from the Congress of the American Diabetes Association (ADA): Orlando 2005 - 65th Annual Scientific Sessions in San Diego, CA, USA, June 10th-14th 2005. Experimental and clinical endocrinology & diabetes: official journal, German Society of Endocrinology [and] German Diabetes Association. 2005; 113(8):475-9.
17. Banarer S, Cryer PE. Hypoglycemia in type 2 diabetes. The Medical clinics of North America. 2004; 88 (4):1107-16, xii-xiii. PMID: 15308392
18. Henderson JN, Allen KV, Deary IJ, Frier BM. Hypoglycaemia in insulin-treated Type 2 diabetes: frequency, symptoms and impaired awareness. Diabetic medicine: a journal of the British Diabetic Association. 2003; 20(12):1016-21. PMID: 14632703
19. Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM. Hypoglycemia in patients with type 2 diabetes mellitus. Archives of internal medicine. 2001; 161(13):1653-9. PMID: 11434798
20. Murata GH, Duckworth WC, Shah JH, Wendel CS, Mohler MJ, Hoffman RM. Hypoglycemia in stable, insulin-treated veterans with type 2 diabetes: a prospective study of 1662 episodes. Journal of diabetes and its complications. 2005; 19(1):10-7. PMID: 15642485
21. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes care. 2003; 26(6):1902-12. PMID: 12766131
22. Leese GP, Wang J, Broomhall J, Kelly P, Marsden A, Morrison W, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes care. 2003; 26(4):1176-80. PMID: 12663593
23. Donnelly LA, Morris AD, Frier BM, Ellis JD, Donnan PT, Durrant R, et al. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabetic medicine: a journal of the British Diabetic Association. 2005; 22(6):749-55.
24. Inkster B, Zammitt NN, Frier BM. Drug-induced hypoglycaemia in type 2 diabetes. Expert opinion on drug safety. 2012; 11(4):597-614. doi: 10.1517/14740338.2012.694424 PMID: 22690846
25. Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health technology assessment. 2010; 14(36):1-248. doi: 10.3310/hta14360 PMID: 20646668
26. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. The Cochrane database of systematic reviews. 2011(10:):CD006423.
27. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. The Cochrane database of systematic reviews. 2008(2:) :CD006739.
28. Swinnen SG, Simon AC, Holleman F, Hoekstra JB, Devries JH. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. The Cochrane database of systematic reviews. 2011(7:):CD006383.
29. Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. The Cochrane database of systematic reviews. 2007(2:):CD005613.
30. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes care. 2005; 28(4):950-5. PMID: 15793205
31. Website. EPHPP. Available from: http://www.ephpp.ca/Tools.html. Accessed 2015 May 7.
32. Higgins JPT GSe. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011.
33. Wong WC, Cheung CS, Hart GJ. Development of a quality assessment tool for systematic reviews of observational studies (QATSO) of HIV prevalence in men having sex with men and associated risk behaviours. Emerging themes in epidemiology. 2008; 5:23. doi: 10.1186/1742-7622-5-23 PMID: 19014686
34. Schopman JE, Simon AC, Hoefnagel SJ, Hoekstra JB, Scholten RJ, Holleman F. The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis. Diabetes/metabolism research and reviews. 2014; 30(1):11-22. doi: 10.1002/dmrr.2470 PMID: 24030920
35. Bunck MC, Diamant M, Corner A, Eliasson B, Malloy JL, Shaginian RM, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes care. 2009; 32(5):762-8. doi: 10.2337/dc08-1797 PMID: 19196887
36. Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V, et al. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. Current medical research and opinion. 2009; 25(1):65-75. doi: 10.1185/03007990802597951 PMID: 19210140
37. Gallwitz B, Bohmer M, Segiet T, Molle A, Milek K, Becker B, et al. Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia. Diabetes care. 2011; 34(3):604-6. doi: 10.2337/dc10-1900 PMID: 21285388
38. Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society. J Clin Endocr Metab. 2013; 98(5):1845-59. doi: 10.1210/jc.2012-4127 PMID: 23589524
39. Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value in Health. 2011; 14(5):665-71. doi: 10.1016/j.jval.2011.02.001 PMID: 21839404
40. Brod M, Pohlman B, Wolden M, Christensen T. Non-severe nocturnal hypoglycemic events: experience and impacts on patient functioning and well-being. Quality of Life Research. 2013; 22(5):997-1004. doi: 10.1007/s11136-012-0234-3 PMID: 22825805
41. Leiter LA, Yale J, Chiasson J, Harris SB, Kleinstiver P, Sauriol L. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes. 2005; 29(3):186-92.
42. Conditions. TNCCfC. Type 2 Diabetes: national clinical guideline for management in primary and secondary care(update). London: Royal College of Physicians 2008. PMID: 21678628
43. Crasto W, Jarvis J, Khunti K, Skinner TC, Gray LJ, Brela J, et al. Multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: the Microalbuminuria Education and Medication Optimisation (MEMO) study. Diabetes research and clinical practice. 2011; 93(3):328-36. doi: 10.1016/j.diabres.2011.05.008 PMID: 21640424
44. Browne D, Avery L, Turner B, Kerr D, Cavan DA. What do patients with diabetes know about their tablets? Diabetic medicine. 2000; 17(7):528-31. PMID: 10972583
45. Lund A, Knop FK. Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on metformin and/or sulphonylurea. Current Medical Research & Opinion. 2012; 28(5):731-6.
46. Monnier L, Wojtusciszyn A, Colette C, Owens D. The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes. Diabetes technology & therapeutics. 2011; 13(8):813-8.
47. Chico A, Vidal-Rios P, Subira M, Novials A. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes care. 2003; 26 (4):1153-7. PMID: 12663589